Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

CLDN18.2-positive Advanced Biliary Tract Cancer

Interventions

DRUG

QLS31905 for Injection

DRUG

Gemcitabine Hydrochloride for Injection

DRUG

Cisplatin for Injection

DRUG

QL2107 Injection

DRUG

Oxaliplatin Injection

DRUG

Capecitabine Tablets

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY